Breast cancer subtypes identified by the ER, PR and HER-2 status in thai women

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 459-462

  Chuthapisith, Suebwong ^a   Permsapaya, Watthanasak ^a   Warnnissorn, Malee ^a   Akewanlop, Charuwan ^a   Sirivatanauksorn, Vorapan ^a   Osoth, Poramaporn Prasarttong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Breast cancer subtype; ER; HER 2; PR; Thai cases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; CANCER GRADING; CANCER INVASION; CLASSIFICATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; THAILAND;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; THAILAND;

EID: 84866467139     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.459     Document Type: Article

References (13)

1. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
2. Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
3. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47.
4. Hudis CA, Gianni L (2011). Triple-negative breast cancer: an unmet medical need. Oncologist, 16, 1-11.
5. Ihemelandu CU, Naab TJ, Mezghebe HM, et al (2008). Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg, 247, 463-9.
6. Kostopoulou E, Vageli D, Kaisaridou D, et al (2007) Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast, 16, 615-24.
7. Kyndi M, Sorensen FB, Knudsen H, et al (2008). Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol, 26, 1419-26.
8. Nguyen PL, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol, 26, 2373-8.
9. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
10. Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23.
11. Sotiriou C, Neo SY, McShane LM, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8.
12. Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91.
13. Wiechmann L, Sampson M, Stempel M, et al (2009). Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol, 16, 2705-10.